Wellgistics Health, Inc. - Common Stock (WGRX)

TAMPA, FL / ACCESS Newswire / May 20, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its board of directors approved the Company's 1-for-50 reverse stock split (the "Reverse Split") of the Company's common stock, par value $0.00001 per share (the "Common Stock"). The Reverse Split was approved by a majority of the stockholders of the Company on April 2, 2026. Post-split, the common stock security will trade under a new CUSIP number.

Datavault AI (NASDAQ: DVLT) announced a binding term sheet with Wellgistics Health (NASDAQ: WGRX) to create DelivMeds AI, a healthcare platform combining AI-driven pharmacy optimization, blockchain-enabled smart contracts, biometric verification and direct-to-consumer healthcare delivery through three concurrent transactions, including an expanded PharmacyChain(TM) license, acquisition of QOLPOM intellectual property and a controlling stake in Tollo Health. The combined transactions carry an expected approximate asset value of $4 billion, subject to an independent fairness opinion, and are intended to support a national rollout of data-driven healthcare delivery and patient engagement solutions.

Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited results

TAMPA, FL / ACCESS Newswire / May 15, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it will report financial results for the first quarter of 2026 on Tuesday, May 19, 2026.

Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA’) tokenization technologies, today entered into a fully binding term sheet (the “Binding Term Sheet”) with Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, to build Wellgistics into DelivMeds AI, a healthcare company that will focus on improving data driven outcomes following the completion of three concurrent transactions: 1) the expansion of Datavault AI’s previously disclosed PharmacyChain™ license (“License”) to include Healthcare-as-a-Service (“HaaS”)-related intellectual property; 2) the acquisition of the QOLPOM intellectual property from EOS Technology Holdings, Inc. (EOS Holdings) and Scilex Holding Company (“Scilex”) (NASDAQ:SCLX) that enables wearables-driven biometric confirmation of pharmacodynamic drug effect and biometric confirmation named-patient to receive home drug delivery; and 3) the acquisition of a controlling stake in Tollo Health, LLC which manufactures unique medical foods and dietary supplements for GLP-1 muscle loss, acute viral infections and chronic viral infection syndromes, proprietary consumer engagement technology, and proprietary marketing channels. Gerald Commissiong has concurrently been appointed Interim Co-CEO of Wellgistics. Together, the three transactions forming DelivMeds carry an expected approximate combined asset value of $4 billion, subject to an independent fairness opinion.

Highlights:

Highlights:

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Wellgistics Health Inc. (NASDAQ: WGRX) resulting from allegations that Wellgistics may have issued materially misleading business information to the investing public.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Wellgistics Health Inc. (NASDAQ: WGRX) resulting from allegations that Wellgistics may have issued materially misleading business information to the investing public.

TAMPA, FL / ACCESS Newswire / March 25, 2026 / Thunder Rock Capital LLC ("Thunder Rock Capital"), a leading investment banking firm specializing in M&A, capital markets, and structured products, served as exclusive M&A advisor to Neuritek Therapeutics, Inc. in connection with its proposed sale to Wellgistics Health, Inc. (Nasdaq:WGRX) (the "Transaction"), pursuant to which Wellgistics is expected to acquire substantially all of the assets and operations of Neuritek, a U.S.-based healthcare technology company focused on next-generation neurological and cognitive health solutions.

TAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President and Interim Chief Executive Officer, Prashant Patel, together with an additional participant from the Company's Board of Directors, entered into agreements with the Company to convert an aggregate of approximately $2.0 million of accrued compensation into shares of the Company's common stock at a conversion price of $0.20 per share, representing a premium to the Company's recent trading price. In connection with the conversion, the Company will issue approximately 10,000,000 shares of common stock.

TAMPA, FL / ACCESS Newswire / March 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President & Interim-CEO Prashant Patel, RPh released a letter to shareholders.

Medical insurance eligibility and benefits verification (EBV) is a core health technology capability necessary for PharmacyChain™ to gain market adoption

GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301

Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum /Besu and Corda (R3) selected as most suitable blockchain platforms to build PharmacyChain™

The prescription drug market still runs through three gatekeepers— CVS Caremark (NYSE: CVS), Cigna’s Express Scripts (NYSE: CI) , and UnitedHealth’s OptumRx (NYSE: UNH) —but the regulatory vise has squeezed out their most profitable practices. The stocks have already taken a beating but might go lower unless they take action now. This disruption in the market creates an opening for alternatives. Wellgistics Health (NASDAQ: WGRX) is building a blockchain and smart‑contract platform designed to monetize prescription flows without relying on the opaque spread pricing and rebate games now under attack. They have exactly what the PBMs need after this crackdown. Additionally, through their partner DataVault, they have the IP to usher in a true digital prescription that cannot be tampered with and contains its own audit trail.

Datavault AI (NASDAQ: DVLT) and Wellgistics Health Inc. (NASDAQ: WGRX) announced plans to expand their existing blockchain-enabled smart contracts partnership beyond prescription tracking to support Wellgistics’ emerging Healthcare as a Service model. The expanded collaboration will integrate additional Datavault AI intellectual property into Wellgistics’ EinsteinRx(TM) and PharmacyChain(TM) platforms to enable secure data integration from pharmacies, hospitals, clinics, diagnostic labs, telehealth providers, wearables and insurers, supporting a hub-and-spoke prescription delivery model and a comprehensive app-based patient engagement solution designed to improve outcomes while reducing total cost of care.

The global blockchain in healthcare market is projected to grow from $11 billion in 2024 to $214 billion by 2030, with annual growth rates expected to exceed 60%

Previously announced partnership with Tollo Health subsidiary TolloCare adding telehealth service offering to drive Wellgistics Pharmacy prescription drug dispending of GLP-1 drugs and promote patient engagement via mental health AI software solution for compliance and to promote lifestyle changes

Tollo Health recently formed subsidiary TolloCare, LLC ('TolloCare') initially targeted to provide telehealth services for GLP-1 and Long COVID patients

Wellgistics Health to leverage EinsteinRx™ AI pharmacy hub and PharmacyChain™ smart contracts to drive healthcare optimization for former NFL players that and rural communities

ATLANTIC CITY, NJ / ACCESS Newswire / January 23, 2026 / DealFlow Events today announced the growing list of companies scheduled to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City.

Feasibility assessment completed, PharmacyChain™ to leverage Datavault AI's edge network and quantum key encryption to improve data driven outcomes in $634 billion prescription drug market

Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy client point-of-sales systems has commenced

TAMPA, FL / ACCESS Newswire / December 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today reminded shareholders of the December 19, 2025 record date (the "Record Date") to receive Dream Bowl 2026 Meme Coin ("Dream Bowl") tokens. All eligible record holders of Wellgistics Health, Inc. common stock will receive one (1) Dream Bowl token for every one (1) share of common stock owned.